Cristina Nanni - Böcker

Nuclear Medicine has greatly contributed to the diagnosis and treament of neuroendocrine neoplasms. This issue of PET Clinics will focus not only on the diagnosis and treatment of neuroendocrine tumors, but also theranostics. Topics include SPECT and other PET tracers, F-DOPA, Ga-DOTA-peptides, Yttrium- and Lutetium-based therapy, and the role of FDG PET. It also covers key information of theranostics.

This issue of PET Clinics focuses on Prostate Cancer Imaging and Therapy, and is edited by Drs. Cristina Nanni and Richard P. Baum. Articles will include: Clinicians Need for Imaging of Prostate Cancer; Imaging of Prostate Cancer using 11C-Choline; Imaging of Prostate Cancer using FACBC; Imaging of Prostate Cancer using Ga-Bombesin; Imaging of Prostate Cancer using 18F-Choline; Imaging of Prostate Cancer using Cu-64 Prostate-specific membrane antigen; From bench to bed: New Gastrin releasing peptide receptor-directed radioligands and their use in prostate cancer; Imaging of Prostate Cancer using Ga-68 Prostate-specific membrane antigen; Imaging of Prostate Cancer using F-18 Prostate-specific membrane antigen; Imaging of Prostate Cancer using uPAR-PET; PET/CT for radiation therapy planning of Prostate Cancer; and more!

In this issue of PET Clinics, guest editors Drs. Cristina Nanni, Paolo Castellucci, Stefano Fanti, and Neeta Pandit-Taskar bring their considerable expertise to the topic of Novel PET Imaging Techniques in the Management of Hematological Malignancies. Top experts in the field discuss the latest radiotracers for lymphoma and myeloma, novel quantitative imaging techniques, radioligand therapies, total body PET imaging; and more.

This book provides a comprehensive overview of the importance of molecular imaging in multiple myeloma, with detailed explanation of its clinical impact. Other important features are the definition of criteria that will aid PET/CT interpretation; identification and explanation of the most frequent pitfalls; a brief overview of the advantages and limitations of DWI MR imaging, still an experimental technique in multiple myeloma; and examination of the possible role of emerging PET tracers. When appropriate, clinical cases are used to illustrate key teaching points. All physicians involved in oncological imaging should regularly reassess and update their routine practice in the evaluation of multiple myeloma patients. This is especially true now, given the recent clarification by the International Myeloma Working Group (IMWG) of the criteria for bone damage requiring therapy and the emerging data supporting the role of the newer functional imaging techniques in predicting outcome and/orevaluating response to therapy. In this challenging context, Molecular Imaging in Multiple Myeloma will be of high value for nuclear medicine physicians, radiologists, and hematologists.

This book provides a comprehensive overview of the importance of molecular imaging in multiple myeloma, with detailed explanation of its clinical impact.

This atlas is intended to enable nuclear medicine practitioners who routinely read PET/CT scans to recognize the most common CT abnormalities. Reading PET/CT scans can sometimes be challenging. It is not infrequent, in fact, to encounter abnormal findings in CT images (not related to the neoplastic disease under evaluation) that are functionally silent and therefore difficult to interpret for nuclear medicine practitioners. Frequently, these findings are clinically relevant and should be reported, interpreted and compared to previous scans. This may also have an impact on patient management, since expensive tests like PET/CT are expected to provide the highest level of diagnostic information. Generally, CT images associated with a PET scan are acquired in a low-dose modality, and therefore prove to be sub-optimal for CT image interpretation. Sometimes a comparison with a full-resolution and contrast-enhanced CT atlas may be difficult. Low-dose CT slices are thicker than diagnostic CT and offer less anatomical detail, which can affect accuracy in terms of recognizing both anatomical structures and pathological findings.Today it is becoming increasingly common to acquire a standard PET/CT by combining the administration of contrast media and a diagnostic CT; here, too, basic CT reporting skills are needed in clinical practice. This atlas features a chapter on “normal anatomy” (with and without contrast media) that is based on low-dose and full-dose CT images from PET/CT standard acquisition, and which identifies all the relevant anatomical structures. Other chapters (focusing on the thorax, abdomen, pelvis, and musculoskeletal system) present cases with common and uncommon anatomical abnormalities. The addition of new cases with ceCT in this revised second edition rounds out the coverage of PET/CT reporting. Given its scope, the book will be of interest to nuclear medicine physicians, radiologists, and oncologists alike.

Low-dose CT slices are thicker than diagnostic CT and offer less anatomical detail, which can affect accuracy in terms of recognizing both anatomical structures and pathological findings.Today it is becoming increasingly common to acquire a standard PET/CT by combining the administration of contrast media and a diagnostic CT;